Skip to content

The clinical effect of serum hypocretin on stroke-related insomnia

The clinical effect of serum hypocretin on stroke-related insomnia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045443
Enrollment
Unknown
Registered
2021-04-15
Start date
2021-07-01
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke-related insomnia

Interventions

case series:None

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Patients with acute ischemic stroke within 72 hours of first onset (with symptoms associated with sudden neurological impairment); 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Brain CT or MR diagnosis of cerebral hemorrhage or other brain diseases, such as intracranial tumor, abscess, metabolic encephalopathy; 2. There were only isolated visual changes, isolated sensory symptoms (such as numbness), isolated dizziness or vertigo, and no evidence of acute ischemic stroke on craniocerebral imaging (CT or MRI); 3. MRS score > 2; 4. The severity of this acute ischemic stroke resulted in long-term bedridden patients or MRS score > 3; 5. Patients who plan or may have any form of surgery within the next 3 months; 6. Patients who have previously been diagnosed with anxiety or depression disorder and are taking or require long-term use of anti-anxiety/depression medications; 7. Patients with refractory insomnia in the past and need to take drugs to assist sleep for a long time; 8. Women of reproductive age who are pregnant or planning to become pregnant, and women who are breastfeeding; 9. Patients with malignant tumor or other serious non-cardiovascular and cerebrovascular diseases, the expected survival time is less than 3 months; 10. Participated in other clinical drug or device studies within 30 days; 11. Inability to understand and/or comply with study follow-up due to severe cognitive impairment or mental illness.

Design outcomes

Primary

MeasureTime frame
serum hypocretin;

Countries

China

Contacts

Public ContactWang Yang

Shenzhen Second People's Hospital

helenwy1978@163.com+86 18922898155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026